Listing of the Claims:

This listing of the claims replaces all the prior listings of the claims.

1. (CURRENTLY AMENDED) A method of treating a neurological disorder of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of ~~a hexose~~ D-mannose to thereby produce a neurosalutary effect within the eye.

2. (CANCELED)

3. (ORIGINAL) The method of claim 1, further comprising administering to the subject a cAMP modulator.

4. (CURRENTLY AMENDED) The method of claim 3, wherein said cAMP modulator is non-hydrolyzable cAMP analogues, adenylate cyclase activators, macrophage-derived factors that stimulate cAMP, macrophage activators, calcium ionophores, ~~membrane depolarization~~, phosphodiesterase inhibitors, specific phosphodiesterase IV inhibitors, beta2-adrenoreceptor inhibitors or vasoactive intestinal peptide.

5. (CURRENTLY AMENDED) The method of claim 1, further comprising administering to said subject ~~a macrophage-derived factor~~ oncomodulin.

6. (CANCELED)

7. (CURRENTLY AMENDED) The method of claim 5, ~~wherein the macrophage-derived factor is~~ further comprising administering to said subject TGF-β.

8. (ORIGINAL) The method of claim 1, wherein the treatment reverses neuronal damage.

9. (CURRENTLY AMENDED) The method of claim 1, wherein the treatment alleviates [[a]] the neurological disorder.

10. (CURRENTLY AMENDED) The method of claim 1, wherein the neurological disorder is selected from the group consisting of ~~traumatic brain injury, stroke, cerebral aneurism, spinal cord injury, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, diffuse cerebral cortical atrophy, Lewy body dementia, Pick disease, mesolimbocortical~~

~~dementia, thalamic degeneration, Huntington chorea, cortical-striatal-spinal degeneration, cortical-basal ganglionic degeneration, cerebrocerebellar degeneration, familial dementia with spastic paraparesis, polyglucosan body disease, Shy-Drager syndrome, olivopontocerebellar atrophy, progressive supranuclear palsy, dystonia musculorum deformans, Hallervorden-Spatz disease, Meige syndrome, familial tremors, Gilles de la Tourette syndrome, acanthocytic chorea, Friedreich ataxia, Holmes familial cortical cerebellar atrophy, Gerstmann-Straussler-Scheinker disease, progressive spinal muscular atrophy, progressive balbar palsy, primary lateral sclerosis, hereditary muscular atrophy, spastic paraplegia, peroneal muscular atrophy, hypertrophic interstitial polyneuropathy, heredopathia atactica polyneuritiformis~~, optic neuropathy, ophthalmoplegia, retina or optic nerve damage, retinopathy, ocular ischemia, injury to ophthalamic tissue, loss of functional recovery after damage to ocular tissue.

11. (CURRENTLY AMENDED) The method of claim 1, wherein the ~~hexose~~ D-mannose is administered by introduction into a region of neuronal injury.

12.-14. (CANCELED)

15. (CURRENTLY AMENDED) The method of claim 1 wherein the ~~hexose~~ D-mannose is administered topically to the eye of the subject ~~or by intraocular injection~~.

16. (ORIGINAL) The method of claim 1, wherein the subject is a mammal.

17. (ORIGINAL) The method of claim 16, wherein the mammal is a human.

18.-19. (CANCELED)

20. (ORIGINAL) The method of claim 10, wherein the damage to the optic nerve is the result of glaucoma.

21. (ORIGINAL) The method of claim 10, wherein the damage to the retina is the result of macular degeneration.

22. (CURRENTLY AMENDED) An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said packaging material comprises a label which indicates said pharmaceutical may be

administered, for a sufficient term at an effective dose, for treating a neurological disorder of the eye, together with a pharmaceutically acceptable carrier, wherein the pharmaceutical agent comprises D-mannose.

23. (ORIGINAL) The article of claim 22, wherein the article further comprises a cAMP modulator.

24. (ORIGINAL) The article of claim 22, wherein the article further comprises oncomodulin.

25. (ORIGINAL) A pharmaceutical formulation comprising D-mannose and a cAMP modulator, and a pharmaceutically acceptable carrier.

26. (ORIGINAL) The pharmaceutical formulation of claim 25, further comprising oncomodulin.

27. (NEW) The method of claim 1, wherein the mannose is administered intraocularly, periocularly, by retrobulbar injection or perfusion, or by combinations thereof.

28. (NEW) The method of claim 1 wherein the neurological disorder is associated with an injured neuron.

29. (NEW) The method of claim 28, wherein the neuron is injured from mechanical injury.

30. (NEW) The method of claim 28, wherein the neuron is injured from exposure to a toxic compound.

31. (NEW) The method of claim 28, wherein administration results in contact of the mannose to the injured neuron to promote neuronal outgrowth.

32. (NEW) The method of claim 3, wherein the cAMP modulator functions by causing membrane depolarization.

33. (NEW) The method of claim 10, wherein the retinopathy is diabetic retinopathy or retrolental fibroplasia.